Combination of chidamide and PD-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy
CONCLUSION: Our results indicate that the combination of chidamide and PD-1 blockade as maintenance therapy could improve the outcomes of aggressive LBCL patients at high risk of failing CAR-T cell therapy.PMID:38615378 | DOI:10.1016/j.intimp.2024.112014
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Zhenhao Wang Hao Xu Yu Mei Min Xiao Yang Cao Liang Huang Zhuming Yang Yicheng Zhang Zhiqiang Han Miao Zheng Zhenya Hong Source Type: research
More News: Allergy & Immunology | Genetics | Immunotherapy | Lymphoma | Stem Cell Therapy | Stem Cells | Transplants